Fosamprenavir: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Fosamprenavir, better known as Lexiva, (3nu4)"/> ===Better Known as: Lexiva or Telzir=== ... |
David Canner (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
* Major Indication: [[Human Immunodeficiency Virus]] Infection<br /> | * Major Indication: [[Human Immunodeficiency Virus]] Infection<br /> | ||
* Drug Class: [[HIV Protease]] Inhibitor | * Drug Class: [[HIV Protease]] Inhibitor | ||
* Date of FDA Approval (Discontinued): 2003 ( | * Date of FDA Approval (Discontinued): 2003 (2017) <br /> | ||
* 2004 Sales: ~$50 Million | * 2004 Sales: ~$50 Million | ||
* Importance: As a prodrug, It is rapidly metabolized by the liver into its active form, also known as [[Amprenavir]]. As a prodrug, it is a slow release form of Amprenavir, thus requiring less frequent dosing. It was one of the first instances of a successful drug stemming from joint ventures of major pharmaceutical companies. | * Importance: As a prodrug, It is rapidly metabolized by the liver into its active form, also known as [[Amprenavir]]. As a prodrug, it is a slow release form of Amprenavir, thus requiring less frequent dosing. It was one of the first instances of a successful drug stemming from joint ventures of major pharmaceutical companies. | ||
